Michael Barbella, Managing Editor11.21.22
Elixir Medical has appointed Alexey (Alex) Nepogodiev as executive vice president, Global Marketing.
Nepogodiev has more than 20 years of leadership experience in successfully developing new markets and therapies in interventional cardiology, structural heart, and endovascular businesses worldwide.
“Alex’s global leadership in developing and establishing diverse therapies across important market segments will be critical as Elixir expands its portfolio of products in interventional cardiology and peripheral vascular markets,” Elixir Medical President and Chief Operating Officer Vinayak Bhat, Ph.D, said.
Most recently, Nepogodiev was divisional vice president of Global Marketing for Abbott Vascular, where he was responsible for the long-term strategy and marketing of the division’s coronary, endovascular, imaging and physiology portfolios. Prior to that, Nepogodiev led the global marketing function for Abbott Structural Heart and its portfolio of transcatheter valve and congenital heart disease technologies, with a major focus on market development. He has also held roles of increasing responsibility at Medtronic plc, where he contributed to the development and launch of multiple generations of drug-eluting stents and other vascular technologies.
Alex earned a bachelor’s degree in marketing from Western Michigan University and an MBA from Thunderbird School of Global Management at Arizona State University.
“Elixir’s disruptive innovation will enable clinical therapies to be available to clinicians for their patients globally,” said Nepogodiev. “I am honored to join such a dynamic organization, and excited about becoming a part of the leadership team.”
A privately-funded company based in Milpitas, Calif., Elixir Medical develops next-generation platforms to treat coronary and peripheral artery disease that are designed to restore the adaptive remodeling and pulsatile motion capabilities of the blood vessel. The company’s mission is to transform the care of patients with heart and vascular disease through innovation.
Nepogodiev has more than 20 years of leadership experience in successfully developing new markets and therapies in interventional cardiology, structural heart, and endovascular businesses worldwide.
“Alex’s global leadership in developing and establishing diverse therapies across important market segments will be critical as Elixir expands its portfolio of products in interventional cardiology and peripheral vascular markets,” Elixir Medical President and Chief Operating Officer Vinayak Bhat, Ph.D, said.
Most recently, Nepogodiev was divisional vice president of Global Marketing for Abbott Vascular, where he was responsible for the long-term strategy and marketing of the division’s coronary, endovascular, imaging and physiology portfolios. Prior to that, Nepogodiev led the global marketing function for Abbott Structural Heart and its portfolio of transcatheter valve and congenital heart disease technologies, with a major focus on market development. He has also held roles of increasing responsibility at Medtronic plc, where he contributed to the development and launch of multiple generations of drug-eluting stents and other vascular technologies.
Alex earned a bachelor’s degree in marketing from Western Michigan University and an MBA from Thunderbird School of Global Management at Arizona State University.
“Elixir’s disruptive innovation will enable clinical therapies to be available to clinicians for their patients globally,” said Nepogodiev. “I am honored to join such a dynamic organization, and excited about becoming a part of the leadership team.”
A privately-funded company based in Milpitas, Calif., Elixir Medical develops next-generation platforms to treat coronary and peripheral artery disease that are designed to restore the adaptive remodeling and pulsatile motion capabilities of the blood vessel. The company’s mission is to transform the care of patients with heart and vascular disease through innovation.